Results 291 to 300 of about 137,029 (384)

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial

Circulation, 2003
E. Chung, M. Packer, K. Lo, A. Fasanmade, J. Willerson   +4 more
semanticscholar   +1 more source

First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

Clinical Pharmacology &Therapeutics, Volume 118, Issue 1, Page 164-176, July 2025.
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its ...
Nassr Nassr, Faiza Rharbaoui, Dietmar Weitz, Johann Gassenhuber, Markus Rehberg, Markus Kohlmann, Fabienne Schumacher, Amel Lahmar, Andreas Kovar, Laurent Perrin, Frank‐Dietrich Wagner, Maria Wiekowski, Mai Anh Nguyen   +12 more
wiley   +1 more source

Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Gastroenterol
Zhang M, Li M, Ou Y, Huang Q, Leng M, Yang X, Yang T.   +6 more
europepmc   +1 more source

Combined Effects of Intermittent Hypoxia and Amyloid Beta on Hippocampal Activity, Its Cholinergic Modulation, and Memory

Hippocampus, Volume 35, Issue 4, July 2025.
ABSTRACT Obstructive sleep apnea (OSA), characterized by repetitive upper airway obstruction, leads to chronic intermittent hypoxia (cIH) and induces cognitive and neuronal network disruptions similar to those observed in Alzheimer's disease (AD). These pathologies are often presented together in the elderly and share some pathophysiological mechanisms.
Laura Pinedo‐Vargas, Felipe Mendez‐Salcido, Jonathan‐Julio Lorea‐Hernández, Victor de Lafuente, Fernando Peña‐Ortega   +4 more
wiley   +1 more source

Infliximab-Induced Pulmonary Sarcoidosis Treated With Upadacitinib: A Case Report and Review of the Literature. [PDF]

Cureus
Swe E, Begun J.
europepmc   +1 more source

FRI0159 Longstanding active giant cell arteritis (gca) treated with infliximab: report of four casesinfliximab

, 2001
Fabrizio Cantini, Laura Niccoli, Carlo Salvarani, Luigi Boiardi, Ignazio Olivieri, Angela Padula   +5 more
openalex   +1 more source

Effects of Stress, Vagal Nerve Stimulation and Disease Activity on Circulating Cytokines, Quantified by an Ultrasensitive Technique, in Ulcerative Colitis: A Pilot Study

JGH Open, Volume 9, Issue 7, July 2025.
ABSTRACT Aims The utility of circulating cytokine concentrations in ulcerative colitis is limited due to poor assay sensitivity. We aimed to examine the relationship of circulating cytokine concentrations, when measured by ultrasensitive detection, to disease activity, response to induction therapy, and physiological stimuli associated with mucosal ...
Tamara Mogilevski, Melinda Y. Hardy, Kazuya Takahashi, Rebecca Smith, Anke L. Nguyen, Adam Farmer, James O. Lindsay, Jason A. Tye‐Din, Qasim Aziz, Peter R. Gibson   +9 more
wiley   +1 more source

Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings. [PDF]

BioDrugs
Kvien TK, Betteridge N, Brückmann I, Bodenmüller W, Bryn G, Danese S, Gonçalves J, Maravic Z, Thorne C, Wingate L, Cornes P.   +10 more
europepmc   +1 more source

FRI0071 Responses to infliximab therapy in the attract trial assess with the disease activity score (das): clinical response measured by das at 102 weeks correlates with arrest of radiologic progression and shows higher response rate than acr20 criteria

, 2001
CE Antoni, Arthur Kavanaugh, B. Manger, Gregory F. Keenan, T Schaible, Gregory R. Harriman, Kalpana S Patel, J. R. Kalden   +7 more
openalex   +1 more source

Frequent Dietetic Involvement Enhances Adherence and Clinical Outcomes of Exclusive Enteral Nutrition in Adults With Crohn's Disease

JGH Open, Volume 9, Issue 7, July 2025.
ABSTRACT Background and Aim Use of Exclusive Enteral Nutrition (EEN) in adults has been limited by lack of defined protocols, poor adherence and perceived lack of efficacy. This study evaluated EEN therapy in adults with Crohn's disease (CD) to identify determinants of clinical efficacy, adherence, and therapy completion.
Matthew K. W. Chu, Alice S. Day, Damjana Bogatic, Martine Hatzi, Samuel K. S. Chu, Samuel P. Costello, Robert V. Bryant   +6 more
wiley   +1 more source